Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings

Addiction

Volumn 108, Issue 3, 2013, Pages 534-544

  Hermanns Clausen, Maren ^a   Kneisel, Stefan ^a   Szabo, Bela ^b   Auwärter, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute toxicity; Aminoalkylindoles; JWH 081; JWH 122; JWH 210; Spice; Synthetic cannabinoids

Indexed keywords

CANNABINOID; PLANT MEDICINAL PRODUCT; STREET DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD; EMERGENCY TREATMENT; FEMALE; HUMAN; MALE; METHODOLOGY; RETROSPECTIVE STUDY; STATISTICS; SUBSTANCE ABUSE; YOUNG ADULT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; CANNABINOIDS; EMERGENCY TREATMENT; FEMALE; HUMANS; MALE; PLANT PREPARATIONS; RETROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 84873974367     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04078.x     Document Type: Article

References (68)

1. UNODC United Nations Office on Drugs and Crime. World Drug Report 2010. 2011. Available at: http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf (accessed 10 December 2011; http://www.webcitation.org/60NzBlRJC).
2. Pertwee R. G., Howlett A. C., Abood M. E., Alexander S. P. H., Di Marzo V., Elphick M. R. etal. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
3. Szabo B., Schlicker E. Effects of cannabinoids on neurotransmission. In: Pertwee R. G., editor. Cannabinoids. Berlin/Heidelberg: Springer-Verlag; 2005, p. 327-365. Available at: http://www.springerlink.com/index/10.1007/3-540-26573-2_11 (accessed 26 July 2011).
4. Pertwee R. G. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-159.
5. Murray R. M., Morrison P. D., Henquet C., Di Forti M. Science and society: cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007; 8: 885-895.
6. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-380.
7. Heifets B. D., Castillo P. E. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009; 71: 283-306.
8. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006; 46: 101-122.
9. Huffman J. W. Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. In: Reggio P. H., editor. The Cannabinoid Receptors. Heidelberg: Springer; 2009, p. 49-94.
10. Pertwee R. G. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005; 168: 1-51.
11. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44: 832-837.
12. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Haishima Y., Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 2009; 57: 439-441.
13. Dresen S., Ferreirós N., Pütz M., Westphal F., Zimmermann R., Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010; 45: 1186-1194.
14. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010; 198: 31-38.
15. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L. etal. Spice: a never ending story? Forensic Sci Int 2009; 191: 58-63.
16. Uchiyama N., Kawamura M., Kikura-Hanajiri R., Goda Y. Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products. Forensic Toxicol 2011; 29: 25-37.
17. Nakajima J., Takahashi M., Nonaka R., Seto T., Suzuki J., Yoshida M. etal. Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays. Forensic Toxicol 2011; 29: 132-141.
18. Nakajima J., Takahashi M., Seto T., Kanai C., Suzuki J., Yoshida M. etal. Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 2011; 29: 95-110.
19. Westphal F., Sönnichsen F. D., Thiemt S. Identification of 1-butyl-3-(1-(4-methyl)naphthoyl)indole in a herbal mixture. Forensic Sci Int 2012; 215: 8-13.
20. Ernst L., Schiebel H.-M., Theuring C., Lindigkeit R., Beuerle T. Identification and characterization of JWH-122 used as new ingredient in 'Spice-like' herbal incenses. Forensic Sci Int 2011; 208: e31-35.
21. Persson H. E., Sjöberg G. K., Haines J. A., de Garbino J. P. Poisoning severity score. Grading of acute poisoning. Clin Toxicol 1998; 36: 205-213.
22. Kneisel S., Auwärter V. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom 2012; 47: 825-835.
23. Dresen S., Gergov M., Politi L., Halter C., Weinmann W. ESI-MS/MS library of 1253 compounds for application in forensic and clinical toxicology. Anal Bioanal Chem 2009; 395: 2521-2526.
24. Ames F. A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Ment Sci 1958; 104: 972-999.
25. Maykut M. O. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 209-238.
26. Green B., Kavanagh D., Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003; 22: 453-460.
27. D'Souza D. C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.-T. etal. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-1572.
28. Morrison P. D., Zois V., McKeown D. A., Lee T. D., Holt D. W., Powell J. F. etal. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 39: 1607-1616.
29. Leweke F. M., Gerth C. W., Klosterkötter J. Cannabis-associated psychosis: current status of research. CNS Drugs 2004; 18: 895-910.
30. Appelboam A., Oades P. J. Coma due to cannabis toxicity in an infant. Eur J Emerg Med 2006; 13: 177-179.
31. Macnab A., Anderson E., Susak L. Ingestion of cannabis: a cause of coma in children. Pediatr Emerg Care 1989; 5: 238-239.
32. Weinberg D., Lande A., Hilton N., Kerns D. L. Intoxication from accidental marijuana ingestion. Pediatrics 1983; 71: 848-850.
33. Jones R. T. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42: 58S-63S.
34. Sontineni S. P., Chaudhary S., Sontineni V., Lanspa S. J. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol 2009; 15: 1264-1266.
35. Donnino M. W., Cocchi M. N., Miller J., Fisher J. Cannabinoid hyperemesis: a case series. J Emerg Med 2011; 40: e63-66.
36. Huffman J. W., Zengin G., Wu M.-J., Lu J., Hynd G., Bushell K. etal. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 2005; 13: 89-112.
37. Aung M. M., Griffin G., Huffman J. W., Wu M., Keel C., Yang B. etal. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 2000; 60: 133-140.
38. Wiley J. L., Compton D. R., Dai D., Lainton J. A., Phillips M., Huffman J. W. etal. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 1998; 285: 995-1004.
39. Showalter V. M., Compton D. R., Martin B. R., Abood M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278: 989-999.
40. Huffman J. W., Mabon R., Wu M. J., Lu J., Hart R., Hurst D. P. etal. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 2003; 11: 539-549.
41. Huffman J. W., Szklennik P. V., Almond A., Bushell K., Selley D. E., He H. etal. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 2005; 15: 4110-4113.
42. Makriyannis A., Deng H. United States Patent no. US 6, 900, 236 B1. 2005: 1-16. Available at http://www.webcitation.org/6BX3mQMrD.
43. Melvin L. S., Milne G. M., Johnson M. R., Subramaniam B., Wilken G. H., Howlett A. C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44: 1008-1015.
44. Compton D. R., Rice K. C., De Costa B. R., Razdan R. K., Melvin L. S., Johnson M. R. etal. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993; 265: 218-226.
45. Atwood B. K., Huffman J., Straiker A., Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010; 160: 585-593.
46. Melvin L. S., Johnson M. R., Harbert C. A., Milne G. M., Weissman A. A cannabinoid derived prototypical analgesic. J Med Chem 1984; 27: 67-71.
47. Mortati K., Dworetzky B., Devinsky O. Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis 2007; 4: 103-106.
48. Bhaskaran M. D., Smith B. N. Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. PLoS ONE 2010; 5: e10683.
49. Bonkowsky J. L., Sarco D., Pomeroy S. L. Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care 2005; 21: 527-528.
50. Tilelli J. A., Spack L. D. Marijuana intoxication presenting as seizure-comment. Pediatr Emerg Care 2006; 22: 141.
51. Müller H., Sperling W., Köhrmann M., Huttner H. B., Kornhuber J., Maler J.-M. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309-310.
52. Hurst D., Loeffler G., McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011; 168: 1119.
53. Mir A., Obafemi A., Young A., Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011; 128: e1622-1627. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22065271 (accessed 20 November 2011).
54. Peglow S., Buchner J., Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict 2012; 21: 287-288.
55. Vearrier D., Osterhoudt K. C. A teenager with agitation. Pediatr Emerg Care 2010; 26: 462-465.
56. Müller H., Huttner H., Köhrmann M., Wielopolski J., Kornhuber J., Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 2010; 43: 152-153.
57. Schneir A. B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012; 8: 62-64.
58. Lapoint J., James L. P., Moran C. L., Nelson L. S., Hoffman R. S., Moran J. H. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011; 49: 760-764.
59. Young A. C., Schwarz E., Medina G., Obafemi A., Feng S.-Y., Kane C. etal. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2011; 30: 1320.e5-13207.
60. Schneir A. B., Cullen J., Ly B. T. 'Spice' girls: synthetic cannabinoid intoxication. J Emerg Med 2010; 40: 296-299.
61. Simmons J., Cookman L., Kang C., Skinner C. Three cases of 'spice' exposure. Clin Toxicol 2011; 49: 431-433.
62. Simmons J. R., Skinner C. G., Williams J., Kang C. S., Schwartz M. D., Wills B. K. Intoxication from smoking 'spice'. Ann Emerg Med 2011; 57: 187-188.
63. Bebarta V. S., Ramirez S., Varney S. M. Spice: a new 'legal' herbal mixture abused by young active duty military personnel. Subst Abuse 2012; 33: 191-194.
64. Dresen S., Kneisel S., Weinmann W., Zimmermann R., Auwärter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 2011; 46: 163-171.
65. Zimmermann U. S., Winkelmann P. R., Pilhatsch M., Nees J. A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of 'spice gold'. Dtsch Arztebl Int 2009; 106: 464-467.
66. Glass M., Dragunow M., Faull R. L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 299-318.
67. Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J. etal. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008; 39: 1533-1541.
68. Muccioli G. G. Blocking the cannabinoid receptors: drug candidates and therapeutic promises. Chem Biodivers 2007; 4: 1805-1827.